Sociedad Argentina de Hematología

ISSN 2250-8309

FORMULARIOS

Declaración de Conflictos de Interés

Cesión de Derechos de Autor


Se solicita enviar ambos formularios a: revista@sah.org.ar

 

 

 

Revista Argentina de Hematología

Abstract

Volumen:    21    # Number : 2

Publication Date :    Mayo - Agosto    Year:    2017

   NUEVAS DROGAS

First generation FLT3 inhibitors sorafenib and midostaurin in acute myeloid leukemia

Authors: Fernández I I

Abstract: FLT3 is one of the most commonly mutated genes in AML, in about 30% of patients (pts). The most frequent mutation that confers poor prognosis is tandem duplication within the juxtamembrane domain of that receptor (FLT3-ITD). Less frequently, point mutations of the tyrosine kinase (TK) domain are detected. Sorafenib and midostaurin are inhibitors of multikinases, not specific for FLT3 mutations and have been evaluated as monotherapy with transient responses in relapsed or refractory (r/r), possibly due to lack of potency and specificity. The results of recent clinical trials show the potential benefit of the ITKs in pts with newly diagnosed AML in combination with standard chemotherapy for induction, consolidation, maintenance and posttransplantation.

Key words: FLT3 inhibitors, Sorafenib, Midostaurin, Acute myeloid leukemia.

Pages :

  Resumen             pdf  

SOCIEDAD ARGENTINA DE HEMATOLOGÍA
Julián Alvarez 146 - Ciudad Autónoma de Bs As - Argentina
(54-11) 4855-2452 / 2485

http://www.sah.org.ar/revista/